Boundless Bio, Inc. (BOLD)
NASDAQ: BOLD · IEX Real-Time Price · USD
4.300
+0.110 (2.63%)
At close: Jul 2, 2024, 4:00 PM
4.340
+0.040 (0.93%)
After-hours: Jul 2, 2024, 7:43 PM EDT
Boundless Bio Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
72
Market Cap
95.69M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 0 | - | - |
| Dec 31, 2022 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionBOLD News
- 27 days ago - Boundless Bio to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference - Business Wire
- 7 weeks ago - Boundless Bio Reports First Quarter 2024 Financial Results and Corporate Highlights - Business Wire
- 2 months ago - Boundless Bio to Present at the Citizens JMP Life Sciences Conference 2024 - Business Wire
- 2 months ago - Boundless Bio Announces First Patient Dosed in First-in-Human Phase 1/2 Clinical Trial of BBI-825 in Cancer Patients with Resistance Gene Amplifications - Business Wire
- 3 months ago - Boundless Bio Presents Preclinical and Clinical Pharmacodynamic Data on its Lead Extrachromosomal DNA (ecDNA)-Directed Therapy, BBI-355, at the American Association for Cancer Research Annual Meeting 2024 - Business Wire
- 3 months ago - Boundless Bio Announces Pricing of Initial Public Offering - Business Wire
- 4 months ago - Oncology biotech Boundless Bio files for a $100 million IPO - Renaissance Capital
- 4 months ago - Boundless Bio Eyes Nasdaq: Unveiling Cancer Therapy Innovation and IPO Ambitions - BNN